FTC Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, a commission may be earned at no additional cost to you. Editorial content is not influenced by affiliate relationships. MedFoundationNC.org is an independent publication — not a medical practice, hospital, or healthcare provider.
Foundayo (orforglipron) is a prescription medication manufactured by Eli Lilly and Company. This article is not medical advice. Consult your physician before starting, stopping, or changing any medication.
By MedFoundationNC.org Editorial Team | Last Updated: April 9, 2026
Your doctor prescribed Foundayo — or you're thinking about asking for it — and now you want to know what happens after you swallow that first pill. The headline-level answer is that Foundayo's side effect profile is consistent with the GLP-1 drug class: gastrointestinal issues are the most common, most side effects occur during dose escalation, and most improve over time. But the headline doesn't tell you what to watch for, what's serious versus normal, or which drug interactions could change your treatment plan. This article does.
Every side effect and interaction discussed below is sourced from the FDA-approved prescribing information for Foundayo (orforglipron), Eli Lilly's published Phase 3 clinical trial data (ATTAIN-1 and ATTAIN-2), or the FDA's April 2026 approval documents.
Common Side Effects: What the Clinical Trials Showed
In Eli Lilly's Phase 3 trials, the following side effects were reported in 5% or more of patients taking Foundayo. These are listed in the FDA-approved labeling:
Foundayo nausea was the most frequently reported side effect, affecting up to 35% of participants in clinical trials. It tends to be worst when you first start the medication and during each dose increase. For most patients, nausea decreases significantly after the body adjusts to each new dose level — which is why the titration schedule builds in at least 30 days at each dose before moving up.
Constipation, diarrhea, and vomiting were the next most common gastrointestinal effects. These follow a similar pattern — most prominent during dose escalation, improving with continued use at a stable dose. Indigestion, stomach pain, bloating, belching, heartburn, and gas were also reported at rates above 5%.
Headache and fatigue were reported as non-gastrointestinal side effects affecting more than 5% of participants.
Foundayo hair loss is listed in the FDA labeling as a common side effect. This has been reported across the GLP-1 drug class and is generally attributed to the rapid weight loss itself (a condition called telogen effluvium) rather than a direct pharmacological effect of the medication. It typically resolves as weight stabilizes.
In clinical trials, treatment discontinuation due to adverse events ranged from 6% to 10% for Foundayo (depending on dose) compared to 4% for placebo. The most common reason for discontinuation was gastrointestinal symptoms. For a broader look at how Foundayo's side effect profile compares to injectable options and the Wegovy pill, our comparison guide includes the published data from each drug's clinical program.
Serious Warnings: The Boxed Warning and What It Means
Foundayo carries a boxed warning regarding thyroid C-cell tumors. This is the most prominent warning in the prescribing information. GLP-1 receptor agonists as a drug class have been associated with thyroid C-cell tumors in rodent studies. The Foundayo prescribing information notes that orforglipron itself did not produce tumors in rodent studies because it is not pharmacologically active in rats or mice — but the human relevance of GLP-1-related thyroid C-cell findings has not been fully determined.
As a result, Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). If you have a family history of thyroid cancer, discuss this with your provider before starting treatment. If you experience symptoms such as a lump in your neck, persistent hoarseness, difficulty swallowing, or shortness of breath while taking Foundayo, contact your healthcare provider immediately.
Other Serious Adverse Events to Monitor
The following serious adverse events are listed in the FDA-approved prescribing information as warnings and precautions. They don't affect most patients, but they require awareness and monitoring:
Pancreatitis. Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. The prescribing information states you should stop taking Foundayo and contact your healthcare provider immediately if you experience severe abdominal pain that doesn't go away — especially pain that radiates to the back, with or without nausea and vomiting.
Gallbladder disease. Gallbladder problems, including gallstones and cholecystitis, have been reported in patients taking GLP-1 medications. Symptoms to watch for include sudden and intense pain in the upper right abdomen, pain between the shoulder blades, nausea, and vomiting.
Severe gastrointestinal events. Beyond the common GI side effects, the prescribing information warns about severe stomach problems. If gastrointestinal symptoms become severe or persistent, contact your provider.
Dehydration and kidney problems. Persistent diarrhea, nausea, and vomiting can lead to dehydration, which can in turn cause kidney injury. The prescribing information emphasizes the importance of staying hydrated, especially during early treatment and dose escalation periods.
Hypoglycemia (low blood sugar). The risk is higher when Foundayo is combined with insulin or sulfonylurea medications. According to published trial data from ATTAIN-2, 7% of patients taking Foundayo in combination with a sulfonylurea reported hypoglycemia, compared to 0.5% of those not on a sulfonylurea. If you take diabetes medications alongside Foundayo, your provider may need to adjust your doses.
Allergic reactions. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. If you develop symptoms of a severe allergic reaction — swelling of the face, lips, tongue, or throat, difficulty breathing, rapid heartbeat, or severe rash — seek emergency medical attention.
Aspiration risk during surgery. Foundayo slows gastric emptying, which can increase the risk of food or liquid entering the lungs during procedures involving anesthesia or deep sedation. Inform your surgical team that you're taking Foundayo before any scheduled procedure.
Foundayo Drug Interactions: What the FDA Labeling Says
Foundayo interacts with other medications through two primary mechanisms: its metabolism through the CYP3A4 enzyme pathway, and its effect on gastric emptying (which can alter absorption of other oral drugs). Based on the FDA-approved labeling, here are the clinically relevant interactions:
Foundayo birth control interaction. Foundayo's delayed gastric emptying may reduce the absorption of oral birth control pills. The prescribing information recommends switching to a non-oral contraceptive method (such as an IUD, vaginal ring, or patch) or adding a barrier method (such as condoms) for 30 days after starting Foundayo and for 30 days after each dose increase. This is important enough that it deserves a direct conversation with your prescriber before you start.
Simvastatin. According to the prescribing information, patients taking Foundayo should not exceed 20 mg of simvastatin daily. Published pharmacokinetic data showed that Foundayo significantly increases levels of simvastatin's active metabolite. If you currently take simvastatin at doses higher than 20 mg, your provider will need to adjust your statin regimen — potentially switching to rosuvastatin or atorvastatin, which were not shown to have clinically relevant interactions with Foundayo.
Strong CYP3A4 inhibitors. If you take medications that strongly inhibit the CYP3A4 enzyme — particularly those that also inhibit the OATP1B transporter — the prescribing information states that you should avoid combining them with Foundayo. If a strong CYP3A4 inhibitor is necessary, the maximum Foundayo dose is capped at 9 mg daily. Common CYP3A4 inhibitors include clarithromycin, cyclosporine, and certain antifungal medications. Check with your pharmacist or prescriber.
Strong CYP3A4 inducers. Medications that strongly induce CYP3A4 — such as carbamazepine, phenytoin, and rifampin — may reduce Foundayo's effectiveness. The prescribing information recommends avoiding these combinations. If you take moderate CYP3A4 inducers, your provider should monitor Foundayo's effectiveness and may need to adjust the dose upward.
Other oral medications. Because Foundayo slows gastric emptying, it can affect the absorption rate of any oral medication taken around the same time. Published pharmacokinetic data showed that acetaminophen absorption was reduced by approximately 28% after the first dose of Foundayo, though this effect diminished with continued use at higher doses. While clinically significant interactions with most oral medications haven't been demonstrated, it's good practice to inform every prescriber and pharmacist that you're on Foundayo so they can monitor accordingly.
Special Populations: Who Needs Extra Consideration
Older adults. In pooled data from the ATTAIN trials, 13% of Foundayo-treated patients were 65 or older and 1% were 75 or older. According to the prescribing information, no overall differences in safety or effectiveness were observed in older adults compared to younger patients.
Pregnancy and breastfeeding. Foundayo has not been studied in pregnant women. Animal studies showed potential harm to the fetus. The medication is not recommended during pregnancy. If you become pregnant while taking Foundayo, stop the medication and contact your provider. A pregnancy exposure registry is available through Eli Lilly at 1-800-545-5979. Whether Foundayo passes into breast milk is not known — breastfeeding is not recommended during treatment.
Severe liver impairment. The prescribing information states that Foundayo is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).
Pediatric patients. Safety and effectiveness have not been established in children. Foundayo is approved for adults only.
Managing Side Effects: Practical Guidance
Based on the FDA labeling and the published clinical trial experience, the most effective strategy for managing GLP-1 side effects is following the Foundayo titration schedule as prescribed. The gradual dose increase exists specifically to give your body time to adjust. Skipping doses or taking higher doses earlier than prescribed increases the risk of severe gastrointestinal symptoms.
Stay hydrated — especially if you experience diarrhea or vomiting. Eat smaller meals. Some clinicians recommend eating slowly and stopping at the first sign of fullness, since GLP-1 medications fundamentally change your hunger and satiety signals. Keep a symptom log during your first few months of treatment so you can give your provider specific information at follow-up appointments.
If you miss a dose, take it as soon as you remember — but don't double up. If you miss seven or more consecutive doses, contact your prescriber before resuming. You may need to restart at a lower dose and re-titrate to reduce the risk of a return of GI symptoms.
For a full understanding of how Foundayo fits into your options — including dosing details, pricing, and how to access it — our comprehensive Foundayo guide covers everything from clinical data to pharmacy access. If you're comparing Foundayo's safety profile against the Wegovy pill or injectable options, our three-way comparison presents the published data side by side. And for readers exploring the broader GLP-1 market, including when pills might be a better fit than injections, our pills vs injections guide can help frame that conversation with your provider. If you're currently on an injectable and experiencing issues, our guide to when GLP-1 injections stop working covers common causes and transition options. For readers evaluating telehealth-based compounded GLP-1 alternatives, our MEDVi analysis and TrimRx evaluation cover different platforms and pricing structures.
Published April 9, 2026. MedFoundationNC.org Editorial Team.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Foundayo (orforglipron) is a prescription medication manufactured by Eli Lilly and Company. All side effect data, drug interaction information, and safety warnings in this article are sourced from the FDA-approved prescribing information and published clinical trial data. Individual responses vary. Consult a licensed healthcare provider about your specific health situation, medications, and risk factors before starting Foundayo. MedFoundationNC.org is an independent editorial publication — not a medical practice, hospital, or healthcare provider.